Immutep (ASX:IMM) has announced that the investigator-initiated EFTISARC-NEO Phase 2 trial evaluating its eftilagimod alpha with radiotherapy plus MSD's KEYTRUDA (pembrolizumab) in the neoadjuvant setting for resectable soft tissue sarcoma has met its primary endpoint. …
Immutep’s efti combination meets primary endpoint in Phase 2 soft tissue sarcoma
May 26, 2025 Australian Biotech
Latest Video
New Stories
-
How can you not be sceptical about a rigged one-sided process?
May 27, 2025 - - Latest News -
Roche advances the development of innovative antibiotic
May 27, 2025 - - Latest News -
Australian-led ENZAMET prostate cancer trial to be presented at ASCO 2025
May 27, 2025 - - Latest News -
Leadership transition for medical affairs professional association
May 26, 2025 - - Latest News -
NSW Government to improve access to ADHD diagnosis and treatment
May 26, 2025 - - Latest News -
Immutep’s efti combination meets primary endpoint in Phase 2 soft tissue sarcoma
May 26, 2025 - - Australian Biotech -
Pharmac proposes change to ensure care continuity for more cancer patients
May 26, 2025 - - Latest News